Put companies on watchlist
SKAN AG
ISIN: CH0013396012
WKN: A0MPG1
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

SKAN AG · ISIN: CH0013396012 · EQS - Company News (24 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1623851
03 May 2023 06:52PM

Annual General Meeting of SKAN Group AG approves all proposals


SKAN AG / Key word(s): AGMEGM
Annual General Meeting of SKAN Group AG approves all proposals

03.05.2023 / 18:52 CET/CEST


Media Information
 

Annual General Meeting of SKAN Group AG approves all proposals

Allschwil, 3 May 2023 – The Annual General Meeting of SKAN Group AG was held today in Basel. At the General Meeting a total of 89.60% of the share capital entitled to vote was represented.

The Annual General Meeting approved all proposals of the Board of Directors. In particular, it approved the distribution of CHF 0.25 per dividend-bearing share, consisting of an ordinary dividend of CHF 0.125 per share and a withholding tax-free distribution from capital reserves of CHF 0.125 per share. The distribution will be made as from 9 May 2023.

The Board members standing for re-election Dr. Gert Thoenen, Oliver Baumann, Cornelia Gehrig, Thomas Huber, Dr. Beat Lüthi, Gregor Plattner and Patrick Schär have been confirmed for another one-year term. Dr Gert Thoenen was re-elected as Chairman of the Board of Directors.

In addition, the Articles of Incorporation were adapted to the new Stock Corporation Law that came into force on 1 January 2023.

The next Annual General Meeting of SKAN Group AG will take place on 7 May 2024.

 


Contacts:

Thomas Balmer, ir@skan.com, +41 79 703 87 28
Alexandre Müller, ir@skan.com, +41 79 635 64 13


Financial calendar:

22 August 2023
26 March 2024
7 May 2024
Publication of Half-Year Results 2023
Publication of Annual Results 2023
Annual General Meeting

 

SKAN – together always one step ahead

SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organization make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organizations) and research laboratories worldwide. Founded in 1968, SKAN today employs over 1170 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, Japan and the USA.


Additional features:

File: SKAN_AGM_3.5.2023


End of Media Release


Language: English
Company: SKAN AG
Kreuzstrasse 5
4123 Allschwil
Switzerland
Phone: +41 43 268 32 32
E-mail: info@skan.com
ISIN: CH0013396012
Valor: 1339601
Listed: SIX Swiss Exchange
EQS News ID: 1623851

 
End of News EQS News Service

1623851  03.05.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1623851&application_name=news&site_id=boersengefluester_html
Visual performance / price development - SKAN AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.